The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer

Claudio Vernieri, Alessia Mennitto, Michele Prisciandaro, Veronica Huber, Monica Milano, Lucia Rinaldi, Maria Silvia Cona, Claudia Maggi, Benvenuto Ferrari, Siranoush Manoukian, Gabriella Mariani, Giulia Bianchi, Giuseppe Capri, Licia Rivoltini, Filippo de Braud

Research output: Contribution to journalArticle

Abstract

Platinum salts are active against metastatic triple negative breast cancer (mTNBC), and biomarkers to predict their effectiveness are urgently needed. In recent years, the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) have emerged as prognostic biomarkers in many malignancies, but their predictive role in platinum-treated mTNBC patients remains unexplored. We performed a retrospective, single centre study to evaluate the association between baseline NLR or PLR and progression free survival (PFS) of mTNBC patients treated with platinum-based chemotherapy. As a control population, we analysed data from patients with hormone receptor-positive HER2-negative (HR+ HER2-) metastatic breast cancer. Among 57 mTNBC patients treated with the carboplatin-paclitaxel or carboplatin-gemcitabine combination, high NLR and PLR were associated with significantly lower PFS at both univariate and multivariable analysis. Conversely, we did not find a significant association between NLR or PLR and the PFS of 148 patients in the control population. Our findings suggest that the NLR and PLR are predictive of benefit from platinum-containing chemotherapy specifically in mTNBC patients. If validated in larger prospective studies, these easy-to-measure parameters could be combined with emerging predictive biomarkers, such as BRCA 1/2 mutations, to improve the selection of mTNBC patients more likely to benefit from platinum-based chemotherapy.

Original languageEnglish
Pages (from-to)8703
JournalScientific Reports
Volume8
Issue number1
DOIs
Publication statusPublished - Jun 7 2018

Fingerprint

Triple Negative Breast Neoplasms
Platinum
Neutrophils
Blood Platelets
Lymphocytes
Drug Therapy
Disease-Free Survival
Carboplatin
gemcitabine
Biomarkers
Tumor Biomarkers
Paclitaxel
Population
Salts
Hormones
Prospective Studies

Cite this

The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer. / Vernieri, Claudio; Mennitto, Alessia; Prisciandaro, Michele; Huber, Veronica; Milano, Monica; Rinaldi, Lucia; Cona, Maria Silvia; Maggi, Claudia; Ferrari, Benvenuto; Manoukian, Siranoush; Mariani, Gabriella; Bianchi, Giulia; Capri, Giuseppe; Rivoltini, Licia; de Braud, Filippo.

In: Scientific Reports, Vol. 8, No. 1, 07.06.2018, p. 8703.

Research output: Contribution to journalArticle

@article{3c389ee04fd64b5eaae89625c729122e,
title = "The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer",
abstract = "Platinum salts are active against metastatic triple negative breast cancer (mTNBC), and biomarkers to predict their effectiveness are urgently needed. In recent years, the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) have emerged as prognostic biomarkers in many malignancies, but their predictive role in platinum-treated mTNBC patients remains unexplored. We performed a retrospective, single centre study to evaluate the association between baseline NLR or PLR and progression free survival (PFS) of mTNBC patients treated with platinum-based chemotherapy. As a control population, we analysed data from patients with hormone receptor-positive HER2-negative (HR+ HER2-) metastatic breast cancer. Among 57 mTNBC patients treated with the carboplatin-paclitaxel or carboplatin-gemcitabine combination, high NLR and PLR were associated with significantly lower PFS at both univariate and multivariable analysis. Conversely, we did not find a significant association between NLR or PLR and the PFS of 148 patients in the control population. Our findings suggest that the NLR and PLR are predictive of benefit from platinum-containing chemotherapy specifically in mTNBC patients. If validated in larger prospective studies, these easy-to-measure parameters could be combined with emerging predictive biomarkers, such as BRCA 1/2 mutations, to improve the selection of mTNBC patients more likely to benefit from platinum-based chemotherapy.",
author = "Claudio Vernieri and Alessia Mennitto and Michele Prisciandaro and Veronica Huber and Monica Milano and Lucia Rinaldi and Cona, {Maria Silvia} and Claudia Maggi and Benvenuto Ferrari and Siranoush Manoukian and Gabriella Mariani and Giulia Bianchi and Giuseppe Capri and Licia Rivoltini and {de Braud}, Filippo",
year = "2018",
month = "6",
day = "7",
doi = "10.1038/s41598-018-27075-z",
language = "English",
volume = "8",
pages = "8703",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer

AU - Vernieri, Claudio

AU - Mennitto, Alessia

AU - Prisciandaro, Michele

AU - Huber, Veronica

AU - Milano, Monica

AU - Rinaldi, Lucia

AU - Cona, Maria Silvia

AU - Maggi, Claudia

AU - Ferrari, Benvenuto

AU - Manoukian, Siranoush

AU - Mariani, Gabriella

AU - Bianchi, Giulia

AU - Capri, Giuseppe

AU - Rivoltini, Licia

AU - de Braud, Filippo

PY - 2018/6/7

Y1 - 2018/6/7

N2 - Platinum salts are active against metastatic triple negative breast cancer (mTNBC), and biomarkers to predict their effectiveness are urgently needed. In recent years, the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) have emerged as prognostic biomarkers in many malignancies, but their predictive role in platinum-treated mTNBC patients remains unexplored. We performed a retrospective, single centre study to evaluate the association between baseline NLR or PLR and progression free survival (PFS) of mTNBC patients treated with platinum-based chemotherapy. As a control population, we analysed data from patients with hormone receptor-positive HER2-negative (HR+ HER2-) metastatic breast cancer. Among 57 mTNBC patients treated with the carboplatin-paclitaxel or carboplatin-gemcitabine combination, high NLR and PLR were associated with significantly lower PFS at both univariate and multivariable analysis. Conversely, we did not find a significant association between NLR or PLR and the PFS of 148 patients in the control population. Our findings suggest that the NLR and PLR are predictive of benefit from platinum-containing chemotherapy specifically in mTNBC patients. If validated in larger prospective studies, these easy-to-measure parameters could be combined with emerging predictive biomarkers, such as BRCA 1/2 mutations, to improve the selection of mTNBC patients more likely to benefit from platinum-based chemotherapy.

AB - Platinum salts are active against metastatic triple negative breast cancer (mTNBC), and biomarkers to predict their effectiveness are urgently needed. In recent years, the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) have emerged as prognostic biomarkers in many malignancies, but their predictive role in platinum-treated mTNBC patients remains unexplored. We performed a retrospective, single centre study to evaluate the association between baseline NLR or PLR and progression free survival (PFS) of mTNBC patients treated with platinum-based chemotherapy. As a control population, we analysed data from patients with hormone receptor-positive HER2-negative (HR+ HER2-) metastatic breast cancer. Among 57 mTNBC patients treated with the carboplatin-paclitaxel or carboplatin-gemcitabine combination, high NLR and PLR were associated with significantly lower PFS at both univariate and multivariable analysis. Conversely, we did not find a significant association between NLR or PLR and the PFS of 148 patients in the control population. Our findings suggest that the NLR and PLR are predictive of benefit from platinum-containing chemotherapy specifically in mTNBC patients. If validated in larger prospective studies, these easy-to-measure parameters could be combined with emerging predictive biomarkers, such as BRCA 1/2 mutations, to improve the selection of mTNBC patients more likely to benefit from platinum-based chemotherapy.

U2 - 10.1038/s41598-018-27075-z

DO - 10.1038/s41598-018-27075-z

M3 - Article

VL - 8

SP - 8703

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

ER -